Equities research analysts at Raymond James boosted their FY2025 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a report released on Monday, February 3rd. Raymond James analyst M.

Stock analysts at Raymond James boosted their Q4 2024 earnings per share (EPS) estimates for Agnico Eagle Mines in a research note issued to investors on Monday, February 3rd. Raymond James analyst F.

This was the stock's second consecutive day of gains.

Fintel reports that on February 6, 2025, Raymond James downgraded their outlook for Symbotic (NasdaqGM:SYM) from Outperform ...

Find insight on Suncor Energy, Petronas, Orsted, and more in the latest Market Talks covering Energy and Utilities.

LPL Financial welcomes a $345 million investment and planning team from Ameriprise as RayJay's employee advisor arm adds a ...

Raymond James Financial, a leading financial services company, has announced its robust first-quarter performance for Fiscal ...

Raymond James analyst James Rollyson raised the firm’s price target on NOV Inc. (NOV) to $19 from $18 and keeps an Outperform rating on the ...

Raymond James lowered the firm’s price target on Corpay (CPAY) to $417 from $434 and keeps an Outperform rating on the shares. Corpay reported ...

Jarrod Biebel, a former Raymond James advisor, has created TrekNorth Investment Management in the Denver area, while James ...

But the day after American Airlines Flight 5342 collided with a U.S. Army helicopter in Washington, D.C., killing all 67 ...